NASDAQ | Common Stock
Tectonic Therapeutic, Inc., a clinical stage biotechnology company focuses on the discovery and development of therapeutic proteins and antibodies to modulate the activity of G-protein coupled receptors(GPCRs).
It offers GEODe technology platform to enable the discovery and development of GPCR-targeted biologic medicines.
The company's pipeline products include RXFP1 agonist, which is in ongoing phase 1a and 1b for the indication of heart failure with preserved ejection fraction; GPCR antagonist for indication of hereditary hemorrhagic telangiectasia; bi-functional GPCR modulator for indication of fibrosis; and GPCR modulators.
Tectonic Therapeutic, Inc. is based in Watertown, Massachusetts.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 9, 24 | -1.82 Increased by +73.18% | - |
| Mar 20, 24 | -2.36 Increased by +65.59% | - |
| Nov 9, 23 | -5.81 Increased by +7.65% | - |
| Aug 10, 23 | 18.29 Increased by +337.35% | - |
| May 11, 23 | -6.80 Increased by +16.99% | - |
| Mar 23, 23 | -6.86 Increased by +11.60% | - |
| Nov 8, 22 | -6.30 Increased by +29.81% | - |
| Aug 9, 22 | -7.70 Decreased by -943.52% | - |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Jun 30, 24 | 0.00 Decreased by N/A% | -12.67 M Decreased by -21.20% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 24 | N/A Decreased by N/A% | -6.81 M Increased by +33.85% | - - |
| Dec 31, 23 | N/A - | -8.79 M - | - - |
| Sep 30, 23 | 0.00 - | -21.58 M - | Decreased by N/A% - |
| Jun 30, 23 | 0.00 - | -10.46 M - | Decreased by N/A% - |
| Dec 31, 22 | 0.00 - | -10.29 M - | Decreased by N/A% - |